Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197

Fina Biosolutions has selected Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM₁₉₇conjugate vaccine carrier protein.

The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, scale-up, and cGMP bulk drug substance manufacturing of CRM₁₉₇, a genetically detoxified diphtheria toxin widely used in conjugate vaccines. FinaBio markets their CRM₁₉₇ under the tradename EcoCRM^®.

Read complete press release.